Pemetrexed Disodium Heptahydrate

For research use only. Not for therapeutic Use.

  • CAT Number: R015465
  • CAS Number: 357166-29-1
  • Molecular Formula: C20H33N5Na2O13
  • Molecular Weight: 597.48
  • Purity: ≥95%
Inquiry Now

Pemetrexed disodium heptahydrate(Cat No.:R015465)is a chemotherapy agent used primarily in the treatment of non-small cell lung cancer and malignant pleural mesothelioma. As a multi-targeted antifolate, it inhibits several enzymes involved in folate metabolism, including thymidylate synthase, leading to disrupted DNA synthesis and cancer cell proliferation. The disodium heptahydrate formulation enhances solubility and bioavailability, facilitating its use in clinical settings. Pemetrexed is often administered in combination with other drugs to improve therapeutic outcomes. 


Catalog Number R015465
CAS Number 357166-29-1
Synonyms

N-[4-[2-(2-amino-4,7-dihydro-4-oxo-3H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt Heptahydrate

Molecular Formula C20H33N5Na2O13
Purity ≥95%
Storage -20°C
IUPAC Name disodium;(2S)-2-[[4-[2-(2-amino-4-oxo-3,7-dihydropyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioate;heptahydrate
InChI InChI=1S/C20H21N5O6.2Na.7H2O/c21-20-24-16-15(18(29)25-20)12(9-22-16)6-3-10-1-4-11(5-2-10)17(28)23-13(19(30)31)7-8-14(26)27;;;;;;;;;/h1-2,4-5,9,13H,3,6-8H2,(H,23,28)(H,26,27)(H,30,31)(H4,21,22,24,25,29);;;7*1H2/q;2*+1;;;;;;;/p-2/t13-;;;;;;;;;/m0........./s1
InChIKey QJVSMHJWAOSBMD-MYXYZBIASA-L
SMILES C1=CC(=CC=C1CCC2=CNC3=C2C(=O)NC(=N3)N)C(=O)N[C@@H](CCC(=O)[O-])C(=O)[O-].O.O.O.O.O.O.O.[Na+].[Na+]
Reference

</br>1: Liu Y, Yin TJ, Zhou R, Zhou S, Fan L, Zhang RG. Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol. 2013 Nov;72(5):1125-32. doi: 10.1007/s00280-013-2299-2. Epub 2013 Sep 26. Review. PubMed PMID: 24067998.</br>2: Boons CC, VAN Tulder MW, Burgers JA, Beckeringh JJ, Wagner C, Hugtenburg JG. The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer Res. 2013 Sep;33(9):3553-61. Review. PubMed PMID: 24023280.</br>3: Genova C, Rijavec E, Truini A, Coco S, Sini C, Barletta G, Dal Bello MG, Alama A, Savarino G, Pronzato P, Boccardo F, Grossi F. Pemetrexed for the treatment of non-small cell lung cancer. Expert Opin Pharmacother. 2013 Aug;14(11):1545-58. doi: 10.1517/14656566.2013.802774. Epub 2013 May 17. Review. PubMed PMID: 23683110.</br>4: Tomasini P, Greillier L, Khobta N, Barlesi F. The place of pemetrexed in the management of non-small-cell lung cancer patients. Expert Rev Anticancer Ther. 2013 Mar;13(3):257-66. doi: 10.1586/era.12.171. Review. PubMed PMID: 23477511.</br>5: Argiris A, Pennella E, Koustenis A, Hossain AM, Obasaju CK. Pemetrexed in head and neck cancer: a systematic review. Oral Oncol. 2013 Jun;49(6):492-501. doi: 10.1016/j.oraloncology.2013.01.007. Epub 2013 Mar 7. Review. PubMed PMID: 23466170.</br>6: Gilani SN, Gridley R, Searle G, Jegannathen A. Malignant peritoneal mesothelioma (MPM) who responded to rechallenge with cisplatin and pemetrexed with current literature review. BMJ Case Rep. 2013 Jan 3;2013. pii: bcr2012007786. doi: 10.1136/bcr-2012-007786. Review. PubMed PMID: 23291819.</br>7: Qi WX, Tang LN, He AN, Shen Z, Lin F, Yao Y. Erlotinib and pemetrexed as maintenance therapy for advanced non-small-cell lung cancer: a systematic review and indirect comparison. Curr Med Res Opin. 2012 Apr;28(4):643-50. doi: 10.1185/03007995.2012.675880. Epub 2012 Mar 29. Review. PubMed PMID: 22414178.</br>8: Morotti M, Valenzano Menada M, Venturini PL, Mammoliti S, Ferrero S. Pemetrexed disodium in ovarian cancer treatment. Expert Opin Investig Drugs. 2012 Apr;21(4):437-49. doi: 10.1517/13543784.2012.661714. Epub 2012 Feb 13. Review. PubMed PMID: 22324304.</br>9: Qi WX, Tang LN, He AN, Shen Z, Yao Y. Effectiveness and safety of pemetrexed-based doublet versus pemetrexed alone as second-line treatment for advanced non-small-cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2012 May;138(5):745-51. doi: 10.1007/s00432-012-1155-9. Epub 2012 Jan 19. Review. PubMed PMID: 22258853.</br>10: Sørensen JB. Pharmacokinetic evaluation of pemetrexed. Expert Opin Drug Metab Toxicol. 2011 Jul;7(7):919-28. doi: 10.1517/17425255.2011.587411. Epub 2011 May 21. Review. PubMed PMID: 21599552.</br>

Request a Quote